Nanoformulation of PROteolysis TArgeting Chimera targeting ‘undruggable’ c-Myc for the treatment of pancreatic cancer
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Nanoformulation of PROteolysis TArgeting Chimera targeting ‘undruggable’ c-Myc for the treatment of pancreatic cancer
Authors
Keywords
-
Journal
Nanomedicine
Volume 15, Issue 18, Pages 1761-1777
Publisher
Future Medicine Ltd
Online
2020-07-23
DOI
10.2217/nnm-2020-0156
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Caveolin-2 is regulated by BRD4 and contributes to cell growth in pancreatic cancer
- (2020) Feng Jiao et al. Cancer Cell International
- Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy
- (2020) Xin Li et al. Journal of Hematology & Oncology
- Cancer statistics, 2019
- (2019) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Proteolysis targeting chimeric molecules as therapy for multiple myeloma: efficacy, biomarker and drug combinations
- (2019) Su Lin Lim et al. HAEMATOLOGICA
- Erlotinib-Valproic Acid Liquisolid Formulation: Evaluating Oral Bioavailability and Cytotoxicity in Erlotinib-Resistant Non-small Cell Lung Cancer Cells
- (2019) Ketan Patel et al. AAPS PHARMSCITECH
- Daunorubicin oral bioavailability enhancement by surface coated natural biodegradable macromolecule chitosan based polymeric nanoparticles
- (2019) Niyaz Ahmad et al. INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
- The BET inhibitor JQ1 attenuates double-strand break repair and sensitizes models of pancreatic ductal adenocarcinoma to PARP inhibitors
- (2019) Aubrey L. Miller et al. EBioMedicine
- BRD4 PROTAC as a novel therapeutic approach for the treatment of vemurafenib resistant melanoma: Preformulation studies, formulation development and in vitro evaluation
- (2019) Drishti Rathod et al. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
- PES1 promotes BET inhibitors resistance and cells proliferation through increasing c-Myc expression in pancreatic cancer
- (2019) Xin Jin et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Enhancement of oral bioavailability of doxorubicin through surface modified biodegradable polymeric nanoparticles
- (2018) Niyaz Ahmad et al. Chemistry Central Journal
- Microfluidic co-culture of pancreatic tumor spheroids with stellate cells as a novel 3D model for investigation of stroma-mediated cell motility and drug resistance
- (2018) Ji-Hyun Lee et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Improvement of oral efficacy of Irinotecan through biodegradable polymeric nanoparticles through in vitro and in vivo investigations
- (2018) Niyaz Ahmad et al. JOURNAL OF MICROENCAPSULATION
- Protein targeting chimeric molecules specific for bromodomain and extra-terminal motif family proteins are active against pre-clinical models of multiple myeloma
- (2018) Xiaohui Zhang et al. LEUKEMIA
- miRNA and Gene Expression in Pancreatic Ductal Adenocarcinoma
- (2018) Anteneh A. Tesfaye et al. AMERICAN JOURNAL OF PATHOLOGY
- PLGA-Based Nanoparticles in Cancer Treatment
- (2018) Sima Rezvantalab et al. Frontiers in Pharmacology
- Technical aspects of preparing PEG-PLGA nanoparticles as carrier for chemotherapeutic agents by nanoprecipitation method
- (2017) Hassan A. Almoustafa et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells
- (2017) D T Saenz et al. LEUKEMIA
- BET protein proteolysis targeting chimera (PROTAC) exerts potent lethal activity against mantle cell lymphoma cells
- (2017) B Sun et al. LEUKEMIA
- Combinatorial Screening of Pancreatic Adenocarcinoma Reveals Sensitivity to Drug Combinations Including Bromodomain Inhibitor Plus Neddylation Inhibitor
- (2017) Casey G. Langdon et al. MOLECULAR CANCER THERAPEUTICS
- Preparation and characterization of surface-modified PLGA-polymeric nanoparticles used to target treatment of intestinal cancer
- (2017) Niyaz Ahmad et al. Artificial Cells Nanomedicine and Biotechnology
- Targeted Drug Delivery with Polymers and Magnetic Nanoparticles: Covalent and Noncovalent Approaches, Release Control, and Clinical Studies
- (2016) Karel Ulbrich et al. CHEMICAL REVIEWS
- Concepts to Target MYC in Pancreatic Cancer
- (2016) M. Wirth et al. MOLECULAR CANCER THERAPEUTICS
- Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4
- (2015) Jing Lu et al. CHEMISTRY & BIOLOGY
- Gemcitabine resistance in pancreatic ductal adenocarcinoma
- (2015) Yoav Binenbaum et al. DRUG RESISTANCE UPDATES
- Nanomedicine in cancer therapy: Challenges, opportunities, and clinical applications
- (2015) Andreas Wicki et al. JOURNAL OF CONTROLLED RELEASE
- Piperlongumine for Enhancing Oral Bioavailability and Cytotoxicity of Docetaxel in Triple-Negative Breast Cancer
- (2015) Ketan Patel et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Principles of nanoparticle design for overcoming biological barriers to drug delivery
- (2015) Elvin Blanco et al. NATURE BIOTECHNOLOGY
- Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma
- (2015) Pawel K Mazur et al. NATURE MEDICINE
- Pancreatic cancer: from state-of-the-art treatments to promising novel therapies
- (2015) Ignacio Garrido-Laguna et al. Nature Reviews Clinical Oncology
- KrasG12D induces EGFR-MYC cross signaling in murine primary pancreatic ductal epithelial cells
- (2015) S Diersch et al. ONCOGENE
- BRD4 promotes pancreatic ductal adenocarcinoma cell proliferation and enhances gemcitabine resistance
- (2015) YONG-HUI WANG et al. ONCOLOGY REPORTS
- Passively Targeted Curcumin-Loaded PEGylated PLGA Nanocapsules for Colon Cancer Therapy In Vivo
- (2015) Rebecca Klippstein et al. Small
- Small-Molecule Control of Intracellular Protein Levels through Modulation of the Ubiquitin Proteasome System
- (2014) Dennis L. Buckley et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- BET bromodomain proteins are required for glioblastoma cell proliferation
- (2014) Chiara Pastori et al. Epigenetics
- A modular and flexible ESC-based mouse model of pancreatic cancer
- (2014) M. Saborowski et al. GENES & DEVELOPMENT
- Oral delivery of paclitaxel nanocrystal (PNC) with a dual Pgp-CYP3A4 inhibitor: Preparation, characterization and antitumor activity
- (2014) Ketan Patel et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- BET Bromodomain Inhibitors Block Growth of Pancreatic Cancer Cells in Three-Dimensional Collagen
- (2014) V. Sahai et al. MOLECULAR CANCER THERAPEUTICS
- Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer
- (2014) Irfan A. Asangani et al. NATURE
- Activation and repression by oncogenic MYC shape tumour-specific gene expression profiles
- (2014) Susanne Walz et al. NATURE
- An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma
- (2014) Maria Giuseppina Baratta et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- MYC Activation Is a Hallmark of Cancer Initiation and Maintenance
- (2014) M. Gabay et al. Cold Spring Harbor Perspectives in Medicine
- Paclitaxel-loaded stealth liposomes: Development, characterization, pharmacokinetics, and biodistribution
- (2014) Yong Xu et al. Artificial Cells Nanomedicine and Biotechnology
- Deciphering the role of stroma in pancreatic cancer
- (2013) Meghna Waghray et al. CURRENT OPINION IN GASTROENTEROLOGY
- Nanoprecipitation is more efficient than emulsion solvent evaporation method to encapsulate cucurbitacin I in PLGA nanoparticles
- (2013) Aws Alshamsan SAUDI PHARMACEUTICAL JOURNAL
- BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia
- (2012) C. J. Ott et al. BLOOD
- BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
- (2011) Jake E. Delmore et al. CELL
- RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
- (2011) Johannes Zuber et al. NATURE
- Effect of Regular Organic Solvents on Cytochrome P450-Mediated Metabolic Activities in Rat Liver Microsomes
- (2010) D. Li et al. DRUG METABOLISM AND DISPOSITION
- Chemical Inducers of Targeted Protein Degradation
- (2010) Kanak Raina et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- PEGylated PLGA nanoparticles for the improved delivery of doxorubicin
- (2009) Jason Park et al. Nanomedicine-Nanotechnology Biology and Medicine
- Paclitaxel-loaded PEGylated PLGA-based nanoparticles: In vitro and in vivo evaluation
- (2008) Fabienne Danhier et al. JOURNAL OF CONTROLLED RELEASE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search